{
      "Rank": 1,
      "Acronym": [
            "SHIELD"
      ],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "Intravenous injection of CL2020 cells"
      ],
      "ArmGroupInterventionName": [
            "Biological: CL2020 cells"
      ],
      "ArmGroupLabel": [
            "CL2020 cells"
      ],
      "ArmGroupType": [
            "Experimental"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT04261335"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "The purpose of this study is to evaluate the safety and the tolerability of CL2020 cells in hypoxic ischemic encephalopathy neonates with hypothermia therapy. In addition, we will evaluate the efficacy of CL2020 cells for infant development."
      ],
      "BriefTitle": [
            "The Clinical Trial of CL2020 Cells for Neonatal Hypoxic Ischemic Encephalopathy"
      ],
      "CentralContactEMail": [],
      "CentralContactName": [],
      "CentralContactPhone": [],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [],
      "CollaboratorClass": [
            "UNKNOWN"
      ],
      "CollaboratorName": [
            "Life Science Institute, Inc."
      ],
      "CompletionDate": [
            "September 2023"
      ],
      "CompletionDateType": [
            "Anticipated"
      ],
      "Condition": [
            "Hypoxia-Ischemia, Brain"
      ],
      "ConditionAncestorId": [
            "D000010335",
            "D000012818",
            "D000002493",
            "D000009422",
            "D000002561",
            "D000014652",
            "D000002318",
            "D000002534"
      ],
      "ConditionAncestorTerm": [
            "Pathologic Processes",
            "Signs and Symptoms, Respiratory",
            "Central Nervous System Diseases",
            "Nervous System Diseases",
            "Cerebrovascular Disorders",
            "Vascular Diseases",
            "Cardiovascular Diseases",
            "Hypoxia, Brain"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC23",
            "All",
            "BC10",
            "BC14"
      ],
      "ConditionBrowseBranchName": [
            "Symptoms and General Pathology",
            "All Conditions",
            "Nervous System Diseases",
            "Heart and Blood Diseases"
      ],
      "ConditionBrowseLeafAsFound": [
            "Ischemia",
            "Ischemia, Brain",
            "Hypoxia-Ischemia, Brain",
            "Hypoxia",
            "Encephalopathy"
      ],
      "ConditionBrowseLeafId": [
            "M9695",
            "M4946",
            "M21813",
            "M3337",
            "M9237",
            "M4356",
            "M14775",
            "M4894",
            "M4962",
            "M16552",
            "M4935"
      ],
      "ConditionBrowseLeafName": [
            "Ischemia",
            "Brain Ischemia",
            "Hypoxia-Ischemia, Brain",
            "Hypoxia",
            "Hypothermia",
            "Brain Diseases",
            "Signs and Symptoms, Respiratory",
            "Central Nervous System Diseases",
            "Cerebrovascular Disorders",
            "Vascular Diseases",
            "Hypoxia, Brain"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "high",
            "high",
            "high",
            "low",
            "high",
            "low",
            "low",
            "low",
            "low",
            "low"
      ],
      "ConditionMeshId": [
            "D000001927",
            "D000002545",
            "D000020925",
            "D000007511",
            "D000000860"
      ],
      "ConditionMeshTerm": [
            "Brain Diseases",
            "Brain Ischemia",
            "Hypoxia-Ischemia, Brain",
            "Ischemia",
            "Hypoxia"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "N/A"
      ],
      "DesignInterventionModel": [
            "Single Group Assignment"
      ],
      "DesignInterventionModelDescription": [
            "3 + 3 dose escalation study design"
      ],
      "DesignMasking": [
            "None (Open Label)"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [],
      "DetailedDescription": [],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nAt least 36 weeks gestation, and either one of the following criteria (i.-iii.) i. Apgar score \u22645 at 10 minutes ii. Continued resuscitation for at least 10 minutes iii. pH <7.0 or base deficit \u226516 mmol/L in any blood sample obtained within 60 min of birth\nModerate or severe encephalopathy by a Sarnat criteria\nUndergone therapeutic hypothermia started before six hours of birth, and done for 72 hours continuously\nBirth weight \u22651,800 g\nHeart rate \u2265100/min, and SpO2 \u226590 %\nAble to provide voluntary written consent after receiving adequate information about the study (consent will be obtained from an acceptable representative)\n\nExclusion Criteria:\n\nSuspected or confirmed severe congenital abnormalities or chromosomal anomaly\nPlanned to undergo surgery or radiation therapy\nScheduled to take systemic corticosteroids treatment for over five days\nBlood glucose \u2265 200 mg/dL\nParticipation in another clinical study (not exclude patients in observational studies)\nSuspected or confirmed active and severe infection\nPositive for HBs antigen, HCV antibody, HIV antibody, HTLV-1 antibody or syphilis serum reaction\nHistory of severe hypersensitivity or anaphylactic reaction\nSevere complications"
      ],
      "EnrollmentCount": [
            "9"
      ],
      "EnrollmentType": [
            "Actual"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [
            "No"
      ],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [],
      "InterventionAncestorTerm": [],
      "InterventionArmGroupLabel": [
            "CL2020 cells"
      ],
      "InterventionBrowseBranchAbbrev": [],
      "InterventionBrowseBranchName": [],
      "InterventionBrowseLeafAsFound": [],
      "InterventionBrowseLeafId": [],
      "InterventionBrowseLeafName": [],
      "InterventionBrowseLeafRelevance": [],
      "InterventionDescription": [
            "1.5 million or 15 million cells, IV on day 5 to 14 of birth"
      ],
      "InterventionMeshId": [],
      "InterventionMeshTerm": [],
      "InterventionName": [
            "CL2020 cells"
      ],
      "InterventionOtherName": [],
      "InterventionType": [
            "Biological"
      ],
      "IsFDARegulatedDevice": [
            "No"
      ],
      "IsFDARegulatedDrug": [
            "No"
      ],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [
            "Hypoxia-Ischemia, Brain",
            "Infant, Newborn",
            "Mesenchymal Stem Cells"
      ],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "September 5, 2021"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "September 3, 2021"
      ],
      "LeadSponsorClass": [
            "OTHER"
      ],
      "LeadSponsorName": [
            "Nagoya University"
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Nagoya"
      ],
      "LocationContactEMail": [],
      "LocationContactName": [],
      "LocationContactPhone": [],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [],
      "LocationCountry": [
            "Japan"
      ],
      "LocationFacility": [
            "Nagoya University Hospital"
      ],
      "LocationState": [
            "Aich"
      ],
      "LocationStatus": [],
      "LocationZip": [
            "466-8560"
      ],
      "MaximumAge": [
            "14 Days"
      ],
      "MinimumAge": [
            "4 Days"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "The Evaluation of Safety and Tolerability of CL2020 in Neonatal Hypoxic Ischemic Encephalopathy Patients With Therapeutic Hypothermia in the Dose Escalation Clinical Trial"
      ],
      "OrgClass": [
            "OTHER"
      ],
      "OrgFullName": [
            "Nagoya University"
      ],
      "OrgStudyId": [
            "CAMCR-014"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "Department of Center for Maternal Neonatal Care, Nagoya University Hospital"
      ],
      "OverallOfficialName": [
            "Yoshiaki Sato, MD, PhD"
      ],
      "OverallOfficialRole": [
            "Principal Investigator"
      ],
      "OverallStatus": [
            "Active, not recruiting"
      ],
      "OversightHasDMC": [
            "Yes"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 1"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "December 2021"
      ],
      "PrimaryCompletionDateType": [
            "Anticipated"
      ],
      "PrimaryOutcomeDescription": [
            "Any adverse events are summarized."
      ],
      "PrimaryOutcomeMeasure": [
            "Incidence of adverse events"
      ],
      "PrimaryOutcomeTimeFrame": [
            "until 12 weeks after the administration"
      ],
      "ReferenceCitation": [
            "Matsuyama N, Shimizu S, Ueda K, Suzuki T, Suzuki S, Miura R, Katayama A, Ando M, Mizuno M, Hirakawa A, Hayakawa M, Sato Y. Safety and tolerability of a multilineage-differentiating stress-enduring cell-based product in neonatal hypoxic-ischaemic encephalopathy with therapeutic hypothermia (SHIELD trial): a clinical trial protocol open-label, non-randomised, dose-escalation trial. BMJ Open. 2022 Apr 26;12(4):e057073. doi: 10.1136/bmjopen-2021-057073."
      ],
      "ReferencePMID": [
            "35473726"
      ],
      "ReferenceType": [
            "derived"
      ],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [
            "Nagoya University"
      ],
      "ResponsiblePartyInvestigatorFullName": [
            "Yoshiaki Sato"
      ],
      "ResponsiblePartyInvestigatorTitle": [
            "MD, PhD, Associate Professor at Department of Center for Maternal Neonatal Care, Nagoya University Hospital"
      ],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Principal Investigator"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [
            "jRCT2043190112"
      ],
      "SecondaryIdDomain": [
            "Japan Registry of Clinical Trials"
      ],
      "SecondaryIdLink": [],
      "SecondaryIdType": [
            "Registry Identifier"
      ],
      "SecondaryOutcomeDescription": [
            "Incidence of composite endpoints is summarized.",
            "Mortality is summarized.",
            "Overall survival is summarized.",
            "Duration of continuous respiratory support is summarized.",
            "Duration of continuous use of vasopressors or pulmonary vasodilators is summarized.",
            "Each composite scores are summarized. The higher scores mean a better outcome.",
            "The developmental quotient is summarized. The higher scores mean a better outcome.",
            "Presence of each event is summarized.",
            "Presence of spasticity is summarized. Spasticity is the condition as below: increased muscle tone, or increased deep tendon reflex.",
            "Presence of spasticity is summarized. The definition of epilepsy is the condition based on the International League Against Epilepsy.",
            "MRI score is summarized. The scoring system is based on the report of Barkovich AJ, et al. (AJNR Am J Neuroradiol. 1998 ;19(1):143-9.) . The higher scores mean a worse outcome.",
            "GMFCS score is summarized. The gross motor function can be categorized into 5 different level. The higher scores mean a worse outcome."
      ],
      "SecondaryOutcomeMeasure": [
            "Incidence of composite endpoints (death, continuous respiratory support, and continuous use of vasopressors or pulmonary vasodilators)",
            "Mortality",
            "Overall survival",
            "Duration of continuous respiratory support",
            "Duration of continuous use of vasopressors or pulmonary vasodilators",
            "The composite score of cognitive scale, language scale, motor scale, social-emotional scale, and adaptive behavior scale in Bayley Scales of Infant and Toddler Development Third edition",
            "The developmental quotient in Kyoto Scale of Psychological Development 2001",
            "Presence of 1) head control, 2) roll over, 3) sitting position, 4) crawl, 5) independent gait, and 6) meaningful words",
            "Presence of spasticity",
            "Presence of epilepsy",
            "MRI score",
            "Gross Motor Function Classification System (GMFCS) score"
      ],
      "SecondaryOutcomeTimeFrame": [
            "at 12, 26, 38, 52, and 78 weeks after administration",
            "all of the clinical trial period (up to 44 months)",
            "all of the clinical trial period (up to 44 months)",
            "up to 78 weeks",
            "up to 78 weeks",
            "78 weeks after administration",
            "78 weeks after administration",
            "at 26, 38, 52, and 78weeks after administration",
            "at 12, 26, 38, 52, and 78 weeks after administration",
            "until 78 weeks after administration",
            "at 2, and 78 weeks after administration",
            "at 78 weeks after administration"
      ],
      "SeeAlsoLinkLabel": [],
      "SeeAlsoLinkURL": [],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "March 4, 2020"
      ],
      "StartDateType": [
            "Actual"
      ],
      "StatusVerifiedDate": [
            "September 2021"
      ],
      "StdAge": [
            "Child"
      ],
      "StudyFirstPostDate": [
            "February 7, 2020"
      ],
      "StudyFirstPostDateType": [
            "Actual"
      ],
      "StudyFirstSubmitDate": [
            "February 1, 2020"
      ]
}